AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
JD Supra15h
FDA Can Keep Tirzepatide off the Drug Shortage List, Judge Says
On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
The FDA Cracking Down on Compounded Weight Loss Drugs – Here’s What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
The GLP-1 shortages are over. What happens next?
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now soon they may be unavailable to most.
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
GlobalData on MSN12h
Vivani treats first patient with long-lasting drug implant for weight loss
A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Mother-of-four collapses and vomits blood after injecting 'weight loss jab', triggers warning
Gill Riley, from Warrington, Cheshire, started using the weight-loss injections, which work by mimicking hormones that ...